Common questions about Eliquis (FAQ)
Q: Do I need regular blood tests while taking Eliquis?
According to official product information, routine coagulation monitoring, such as regular INR blood tests, is generally not required for those taking Eliquis. However, your healthcare provider may check your blood cell counts, kidney function, and liver function periodically. These tests may be utilized as part of the overall health assessment before initiating and periodically during treatment.
Q: Are there any foods or drinks I need to avoid while on Eliquis?
Regulatory documents state that Eliquis is not generally affected by Vitamin K intake, unlike some other anticoagulants, and can be taken with or without food. However, official information indicates that caution is appropriate regarding grapefruit juice, as it may increase the drug level in your body. Furthermore, regulatory documents note that moderation or limitation is generally described for alcohol consumption due to the increased bleeding risk.
Q: What happens if I suddenly stop taking Eliquis?
Official safety warnings caution that discontinuing Eliquis suddenly and without the guidance of a healthcare provider increases the risk of serious blood clot-related events, such as a stroke. If the drug is stopped, your risk of a blood clot returning is increased, unless an appropriate alternative medication is immediately started. Official information stresses the importance of only discontinuing treatment under medical supervision.
Q: Is there an antidote or reversal agent for Eliquis?
Regulatory agencies have approved a specific agent, andexanet alfa, that can be used to reverse the blood-thinning effects of apixaban (the active ingredient in Eliquis). This reversal agent is used when a patient experiences life-threatening or uncontrolled bleeding. The existence of this agent is described as a treatment option for managing severe bleeding events or certain emergency procedures.
Q: What are the main risks associated with taking Eliquis?
As an anticoagulant, the main risk associated with Eliquis is bleeding (hemorrhage), which can be minor or serious. Official safety information also includes a specific warning about the risk of a spinal or epidural hematoma—a collection of blood near the spinal cord—if a patient undergoes a procedure like a spinal tap or epidural injection while on the drug. These warnings relate to careful risk assessment and monitoring, as described in regulatory documents.
Q: Can Eliquis cause easy bruising or bleeding gums?
According to the official list of adverse reactions, common side effects include increased bleeding, which patients may notice as easy bruising (hematoma) or blood collection under the skin. Other common signs of the drug's effect are bleeding gums, nosebleeds (epistaxis), or prolonged bleeding from minor cuts. These effects are recognized in the product's safety profile as consistent with its role as an anticoagulant.
Q: Is it normal to feel tired when first starting Eliquis?
Official product information lists anemia, or a low red blood cell count, as a common adverse reaction, which can contribute to a feeling of fatigue. Some regulatory sources also report dizziness and unusual tiredness as possible, though less frequent, side effects. If these reactions are severe or persistent, regulatory guidance suggests seeking consultation with a healthcare provider.
Q: Can I take vitamins or supplements with Eliquis?
Official interaction data indicates that certain supplements, such as the herbal remedy St. John’s Wort, can significantly interfere with how the body metabolizes Eliquis. Regulatory information suggests consulting a healthcare provider before combining supplements, as many lack formal interaction data. Regulatory safety practices emphasize informing a healthcare provider about all substances being taken.
Q: Are there any long-term side effects of taking Eliquis for several years?
Studies and official information indicate that the known adverse effects, particularly the risk of bleeding and anemia, remain the primary concerns during long-term use. Other adverse reactions reported over extended clinical trials, such as difficulty sleeping (insomnia), are also tracked. These risks are described in the drug's safety profile regardless of the duration of therapy.
Q: Is Eliquis safe for people who have had stomach ulcers in the past?
According to regulatory guidelines, Eliquis is contraindicated—meaning it must not be used—in patients with current or recent gastrointestinal ulceration. This restriction is in place because these conditions are considered a significant risk factor for major bleeding. Regulatory guidance requires a healthcare provider to assess a patient’s bleeding risk history before initiating this medication.
Q: Will Eliquis affect my blood pressure?
Official safety documents list hypotension, or abnormally low blood pressure, as an uncommon adverse reaction associated with Eliquis. The drug's mechanism does not primarily target blood pressure, but low blood pressure can occur as a side effect. Regulatory guidance suggests that any noticeable symptoms be reviewed with a healthcare professional.
Q: Can Eliquis be used during pregnancy or while breastfeeding?
Regulatory documents state that use of Eliquis is not recommended for pregnant women. Furthermore, the drug is contraindicated, meaning strictly prohibited, while breastfeeding, because it is not known whether the active ingredient passes into human milk. These restrictions are based on safety concerns for the child and a lack of sufficient data.
Q: What are the most common reasons someone might be told not to use Eliquis?
Official regulatory documents define several key patient groups for whom the medication is restricted or contraindicated. The most significant reasons are the presence of active pathological bleeding or a history of severe allergic reactions to the drug. Other major restrictions relate to certain stages of severe kidney impairment and specific types of severe liver disease that affect clotting.
Q: Is there a generic version of Eliquis available?
According to regulatory approval information, the active ingredient in Eliquis, apixaban, has received generic approvals in some regions. However, the commercial launch of generic versions is currently constrained by patent and exclusivity rights. Therefore, in many markets, the brand-name product remains the only version available.
Q: Does Eliquis need to be taken at the exact same time every day?
Official administration guidance specifies that Eliquis should be taken twice daily. Taking the doses at approximately 12-hour intervals helps to maintain consistent therapeutic levels of the drug in the blood. Maintaining a routine is described as a measure to support consistent therapeutic drug levels.
Q: What recent research has been done on the long-term use of Eliquis?
The clinical evidence reviewed by regulatory bodies includes studies focused on long-term safety and effectiveness. This includes follow-up data from major studies like the ARISTOTLE trial concerning stroke prevention in atrial fibrillation. Dedicated research was also conducted for the extended evaluation of the drug’s role in preventing recurrent venous blood clots (VTE).
Q: Can Eliquis cause changes in mood or sleep?
Official adverse reaction reports list several effects related to sleep and mood. Insomnia (difficulty sleeping) is reported as a common side effect. Furthermore, changes in mood, specifically anxiety and depression, are listed in the official safety profile as uncommon adverse reactions.
Q: What does the patient information leaflet say about alcohol consumption with Eliquis?
According to the official patient information leaflet and regulatory warnings, regulatory warnings note that alcohol consumption is generally recommended to be limited or avoided while taking Eliquis. The reason for this caution is that alcohol may increase the risk of bleeding, which is already a known side effect of the anticoagulant.
Q: What are the key findings from major studies on Eliquis?
The key findings reviewed by regulatory bodies indicate that for stroke prevention in atrial fibrillation, major studies indicated a pattern of association with a reduced rate of major bleeding when compared to warfarin. Additionally, studies showed that for the treatment of venous blood clots (VTE), Eliquis was non-inferior to standard conventional therapy in preventing recurrent clots.
Q: Is Eliquis used to prevent stroke in people who do not have atrial fibrillation?
Official indications state that the drug is approved for stroke prevention mainly in patients diagnosed with nonvalvular atrial fibrillation (NVAF). While the medication is approved for other clot-related conditions, such as preventing deep vein thrombosis (DVT) and pulmonary embolism (PE), the product information does not list stroke prevention in non-AFib populations as an approved use.
Q: What should I tell a healthcare provider before starting Eliquis?
Regulatory safety documentation suggests informing your healthcare provider about all health conditions, especially any active bleeding or history of severe liver or kidney problems. Regulatory safety documentation suggests disclosing all other medications and supplements, including over-the-counter and herbal products like St. John’s Wort. Lastly, official documents indicate the necessity of discussing pregnancy status, plans, or breastfeeding.
